CoQ10: Ubiquinol vs ubiquinone, what the independent evidence shows

Coenzyme Q10 (a fat-soluble molecule that lives inside your mitochondria, the cell's power plants) ferries electrons between Complexes I/II and III of the respiratory chain. No CoQ10, no ATP. So every cell makes its own, and the heart, kidney, and liver hold the highest tissue levels.

It has a second job too. In its reduced form, CoQ10 is the inner membrane's main fat-soluble antioxidant. The molecule flips between two states all day long: ubiquinone (the oxidised form, which picks up two electrons) and ubiquinol (the reduced form, which hands them on, to Complex III or to a free radical it neutralises). That redox cycle is the whole point. When a label just says "CoQ10", it almost always means ubiquinone. Its drug name is ubidecarenone.

In healthy adults, about 95 percent of plasma CoQ10 sits as ubiquinol, because the body keeps reducing it back. Tissue ratios vary by organ.

Ubiquinone vs ubiquinol at a glance.

Three facts explain why CoQ10 became a longevity-adjacent supplement.

Tissue CoQ10 drops with age. A 1989 study (Kalén, Lipids) measured human heart, kidney, liver, and other organs. It found a roughly 50 percent decline between age 20 and age 80.

Statins lower it. Statins block HMG-CoA reductase, which sits upstream of both cholesterol and CoQ10 synthesis (the shared mevalonate pathway). A 2015 meta-analysis (Banach, Pharmacological Research) pooled eight placebo-controlled arms. Statins cut circulating CoQ10 by a weighted mean difference of −0.44 µmol/L (95 % CI −0.52 to −0.37; p < 0.001).

One heart-failure trial hit a positive primary endpoint. Q-SYMBIO (Mortensen 2014, JACC: Heart Failure) gave 300 mg/day of CoQ10 to 420 patients with NYHA class III to IV chronic heart failure (symptoms with light activity or even at rest) for two years. MACE (the trial's composite of unplanned heart-failure hospitalization, cardiovascular death, mechanical circulatory support, or urgent cardiac transplant) fell by half: HR 0.50, 95 % CI 0.32 to 0.80. Two-year all-cause mortality was 10 % on CoQ10 versus 18 % on placebo. The trial used ubiquinone (Pharma Nord's Bio-Quinone), not ubiquinol. The headline ubiquinol bioavailability claim rarely mentions that detail.

From those three observations, a whole supplement industry grew. The story this guide tells is what happened when the retail claim (ubiquinol absorbs 2 to 3x better than ubiquinone) met the independent evidence.

The "2 to 3x more bioavailable" line rests on five studies. Each one has a financial or organisational link to the maker of the ubiquinol product it tested, and all but Hosoe 2007 (which had no ubiquinone arm) report that product as superior. One is not even a human study (Failla 2014 is a cell-culture model). The five are Hosoe 2007, Failla 2014, Langsjoen 2014, Evans 2009 and Mei 2026. Here they are one at a time.

Kaneka Corporation (Japan) launched the world's first commercial food-grade ubiquinol ingredient, KanekaQH, in 2007. It still dominates the ubiquinol market, made by yeast biofermentation. Most credible ubiquinol products in DACH carry the Kaneka seal. Non-Kaneka ubiquinol (mostly Chinese-sourced) is the unspoken low-price tier.

Kaneka has also funded or employed authors on much of the bioavailability literature that backs its own product. Disclosed sponsor relationships are common in supplement science. Flagging them is standard practice (Cochrane's risk-of-bias domain on funding does exactly this). Nothing here alleges scientific misconduct. What you have to weigh is the cumulative pattern.

The studies cited most often for the "2 to 3x more bioavailable" line are these:

• The Hosoe KanekaQH safety and bioavailability study (Regul Toxicol Pharmacol, 2007). The lead author lists a Kaneka Corporation affiliation, and the study tests Kaneka's own ingredient. Single-blind, placebo-controlled, doses 90/150/300 mg, no head-to-head ubiquinone arm.

• The Failla Caco-2 paper (J Agric Food Chem, 2014). The conflict-of-interest statement reads verbatim: "F.A. is an employee of Kaneka North America LLC, the sponsor for this project." This is an in vitro Caco-2 cell digestion model, not a human pharmacokinetic study. The paper itself does not claim otherwise. Watch out for when it gets cited downstream as if it were clinical evidence.

• The Langsjoen ubiquinol-versus-ubiquinone study (Clin Pharmacol Drug Dev, 2014). Open-label fixed-sequence crossover in 12 healthy volunteers. Compared ubiquinone 200 mg/day with ubiquinol 200 mg/day, each over 4 weeks. Both arms used identical softgel excipients (the non-active filler ingredients). The paper carries no conflict-of-interest statement, so the link here is organisational rather than a disclosed financial one. Peter and Alena Langsjoen are long-time officers of the International Coenzyme Q10 Association (ICQA), and Kaneka-affiliated sites distribute their ubiquinol papers.

The same structural pattern (a ubiquinol-product maker funding a bioavailability study of its own product) shows up outside the Kaneka literature too. Two parallel cases:

• The Evans crossover trial (J Funct Foods, 2009). Randomised double-blind crossover in 10 older adults. Compared a Soft-Gel Technologies ubiquinol (CoQH-CF) with a ubiquinone reference. Sponsored by Soft-Gel Technologies, Los Angeles, the maker of the test product. Same structural pattern, different sponsor.

• The Mei cocrystal trial (Clin Pharmacol Drug Dev, 2026). The newest entry. A cocrystal ubiquinol formulation versus a ubiquinone reference, n = 12 healthy adults aged 45 to 65. Both products were taken as a single 240 mg dose on an empty stomach, the set-up where the fat-carrier effect matters least. The headline ratios (Cmax is the peak blood level, AUC is the total exposure over time, and the 90% CI is the range the true value likely sits in):

  • Cmax: 2.20x (90% CI 1.59 to 3.04)
  • AUC₀-ₜ: 2.01x (90% CI 1.51 to 2.70)
  • AUC₀-∞: 3.43x (90% CI 1.47 to 8.00)

  The funding statement reads verbatim: "This work was supported by Cocrystal Health Industry Co., Ltd, Zhejiang, China." The acknowledgements add: "The authors received funding and were supplied the test product and reference product for this specific study by Cocrystal Health Industry Co., Ltd, Zhejiang, China." The published conflict-of-interest declaration says the authors have none. The authors come from three places. Mei is at the Shanghai Institute of Materia Medica (academic). Zhu works at Cocrystal Health, the sponsor. Soni, Kasaraneni and Panchal work at Credevo Pte. Ltd., the contract-research firm whose staff also did the medical writing. Post-hoc power (the chance that a study this size reliably detects a real difference; 80% is the usual target) was thin:

  • Cmax: 29.1%
  • AUC₀-ₜ: 34.1%
  • AUC₀-∞: 10.2% (the parameter with the widest confidence interval, the 1.47 to 8.00 range above)

Put it together, and the body of work behind the 2 to 3x claim shares one feature. Each study has a direct financial or organisational link to the maker of the ubiquinol product it tests. None of these papers is fraudulent. Each looks defensible on its own. What you have to weigh is the cumulative pattern of disclosed sponsor relationships across the literature the 2 to 3x claim rests on.

A note on symmetry. The most-cited counter-review (Mantle & Dybring 2020, covered in the next section) was written by employees of Pharma Nord, the Danish maker of the ubiquinone product used in Q-SYMBIO and KiSel-10. Same lens applied to the other side of the debate. Both manufacturers are disclosed. Both have a commercial interest you should bring into the read.

Research not paid for by ubiquinol makers finds that the carrier lipid (the oil the CoQ10 is dissolved in) and the formulation drive CoQ10 bioavailability, not the redox form. López-Lluch 2019 tested seven formulations head-to-head, and one of the two best absorbers was a ubiquinone. Mantle & Dybring 2020 concluded that the claimed ubiquinol superiority "would appear to be mistaken" (both authors work for ubiquinone maker Pharma Nord, more below). Fladerer & Grollitsch 2023 (28 RCTs) recommends ubiquinone for people with heart failure. The first two papers do most of the work here.

The first is the López-Lluch seven-formulation crossover (Nutrition, 2019, 57:133 to 140). Double-blind crossover in 14 healthy adults, seven different CoQ10 formulations, with at least 4-week washouts between arms. Both ubiquinone and ubiquinol products tested in the same protocol with matched dosing.

The two best-absorbed formulations were soft-gel capsules. One of them was ubiquinone, not ubiquinol. The paper concludes verbatim: "This study highlights the importance of individually adapted selection of best formulations to reach the highest bioavailability of CoQ10 in humans." Translation: the deciding variable was carrier lipid and solubilisation (how well the CoQ10 is dissolved), not redox form. A well-formulated ubiquinone in oil beats a poorly-formulated ubiquinol in a dry capsule.

The second is the Mantle & Dybring review (Antioxidants, 2020), the most-cited CoQ10 bioavailability review of the last five years. The authors re-analyse López-Lluch 2019. They note that ubiquinol's plasma area-under-curve was roughly 2x a poorly-formulated ubiquinone, but only 52% of a properly formulated ubiquinone. Direct quote: "the concept of the superior bioavailability of supplemental ubiquinol compared to ubiquinone would appear to be mistaken."

One caveat. Both Mantle and Dybring work for Pharma Nord, the Danish maker of the Bio-Quinone (Myoqinon) ubiquinone product used in Q-SYMBIO and KiSel-10. That is a counter-industry view, not fully neutral. But Pharma Nord is the competitor showing its hand, not the dominant ingredient supplier. And the underlying mechanism (carrier lipid + solubilisation) is what López-Lluch tested independently.

The pharmacokinetic backstop matters too:

• Plasma equilibrates toward ubiquinol no matter what form you swallow. Ingested ubiquinone gets reduced to ubiquinol during absorption, probably in the lymph, before tissue uptake. Blood tests (HPLC, the standard lab method) routinely find CoQ10 sitting mostly in the reduced form in healthy adults. The "you need to take the reduced form to have the reduced form in your blood" framing is biologically wrong.

• Absorption saturates above about 200 mg per single dose. Splitting the dose (2 x 100 mg) gives a bigger plasma rise than the same 200 mg taken at once. That is why Q-SYMBIO used 100 mg three times daily.

• CoQ10 plasma half-life is roughly 33 hours. Steady state takes about a week.

Then there is the Fladerer & Grollitsch review (Curr Cardiol Rep, 2023). It covers 28 randomized trials and compares the two forms for heart disease. It was written at the University of Graz. One disclosure worth knowing: the lead author works part-time for Apomedica, whose Dr. Böhm brand sells a ubiquinone capsule. That is the same lens we apply to Kaneka and Pharma Nord. The conclusion (verbatim): "the authors recommend CoQ10 [ubiquinone] instead of CoQH2 [ubiquinol] to treat and prevent cardiovascular disease in patients with heart failure." The ubiquinone trials used 60 to 300 mg/day, and some showed fewer cardiovascular deaths in heart failure. The ubiquinol trials used 300 to 600 mg/day, and none reported a mortality benefit.

Weight these by independence and study quality, and the read is this: carrier and dose explain more of the plasma-CoQ10 difference than redox form does, and the one positive cardiovascular outcome trial we have used ubiquinone.

Ubiquinol is a defensible (not proven-superior) pick in three groups: statin users, adults over 60, and people with fat-malabsorption conditions (IBD, cystic fibrosis, post-bariatric, pancreatitis). In all three the case is mechanistic, not RCT-proven: no clean head-to-head ubiquinol-vs-ubiquinone trial exists in any of them in the 2015 to 2026 window. For everyone else, formulation and dose matter more than redox form.

Statin users. Statins lower circulating CoQ10 by a pooled weighted mean difference of −0.44 µmol/L (Banach 2015, Pharmacological Research). The intuition is that the reduced form might restore tissue levels faster, because plasma reductase capacity may be a limiting step in older or polypharmacy patients. The intuition is plausible. The direct evidence is thin. One trial (Taylor 2015, Atherosclerosis) gave 600 mg/day of ubiquinol versus placebo for 8 weeks to 41 patients with confirmed statin myalgia. Pain scores rose on simvastatin no matter which CoQ10 group people were in. There were more pain reports on ubiquinol than placebo (14/20 vs 7/18, p = 0.05). The trial had no ubiquinone arm. No head-to-head ubiquinol-vs-ubiquinone RCT in statin users has been published in the 2015 to 2026 window.

Older adults (60+). Lower gastric acid, less bile flow, and reduced lymphatic transport all make it harder to absorb lipophilic (fat-soluble) compounds as you age. The case for ubiquinol in this group is mechanistic, not RCT-proven. No clean independent head-to-head ubiquinol-vs-ubiquinone trial in a 60+ cohort surfaced in this research. The "better in older adults" claim leans hard on manufacturer-aligned reanalyses.

Fat-malabsorption populations. Cystic fibrosis, IBD, post-bariatric, chronic pancreatitis, advanced liver disease. Anyone whose enterocyte micellarisation (the way the gut wraps fat for absorption) is compromised may absorb the reduced form better. Again, mechanistic plausibility, no direct head-to-head trial.

Fair summary for these three groups: ubiquinol is a defensible default, not a proven superior choice. If the price difference is small, fine. In DACH, oil-softgel ubiquinol costs roughly the same per mg as the Q-SYMBIO ubiquinone softgel. The big gap is to cheap powder ubiquinone, which is roughly 2 to 5x cheaper per mg than typical Kaneka softgels (see the market section below). If that is your comparison, the case is much weaker than the retail messaging on product pages would suggest.

For everyone else (healthy adults under 60, no statin, no malabsorption) the evidence sits closer to "either works, formulation and dose matter more."

CoQ10's strongest clinical evidence is in chronic heart failure (Q-SYMBIO: MACE halved, mortality 10 % vs 18 %) and adult migraine prophylaxis (Sándor 2005, NNT 3). It modestly improves sperm parameters, with no proven effect on pregnancy or live birth. It is genuinely mixed for statin myopathy, clearly negative for Parkinson's and overstated for hypertension. Primary mitochondrial disease is the one true treatment indication. Here is the map, condition by condition.

Heart failure (the strongest signal). Q-SYMBIO (Mortensen 2014, JACC: Heart Failure): 420 patients with NYHA III to IV chronic HF, 300 mg/day for 2 years. MACE HR 0.50 (95 % CI 0.32 to 0.80), 2-year all-cause mortality 10 % vs 18 %, CV mortality 9 % vs 16 %. KiSel-10 (Alehagen 2012/2013, Int J Cardiol; 12-year follow-up Alehagen 2018, PLoS ONE) added selenium plus 200 mg/day CoQ10 to elderly Swedes. At 12 years, cardiovascular deaths were still lower in the supplement group: HR 0.59 (95 % CI 0.42 to 0.81). The ~50 % relative reduction you often see quoted (HR ~0.51) is the earlier 10-year figure. The selenium confound is real. You cannot cleanly ascribe KiSel-10 to CoQ10 alone. Both the 2021 ESC HF guideline (and its 2023 focused update) and the 2022 AHA/ACC/HFSA HF guideline do not include CoQ10 as guideline-directed therapy.

Migraine prophylaxis (modest, replicated). Sándor 2005, Neurology: 42 adult migraine patients, 3 x 100 mg/day for 3 months. 50 %-responder rate 47.6 % on CoQ10 versus 14.4 % on placebo. NNT 3 (you need to treat three patients for one to see a response). A 2021 meta-analysis (Sazali, BMJ Open; 6 studies, n = 371) confirmed reduced attack frequency and duration, but no effect on attack severity. Pediatric trials (Slater 2011, Cephalalgia) are negative. AHS/AAN rate CoQ10 Level C ("possibly effective") for adult migraine prevention, per the 2012 AAN/AHS guideline (Holland, Neurology).

Male sub-fertility (surrogate-marker yes, outcome no). A 2013 meta-analysis (Lafuente, J Assist Reprod Genet; 3 RCTs, 296 men): CoQ10 improved sperm concentration and motility. Pregnancy rates did not rise, and none of the three trials even measured live births. For women in IVF, a 2020 meta-analysis found more clinical pregnancies but no difference in live births (see the fertility FAQ below). Later reviews (Salas-Huetos 2021, Antioxidants; Tang 2022; 2025 World J Men's Health) confirm the surrogate-vs-outcome gap.

Statin-associated muscle symptoms (genuinely mixed). Two competing meta-analyses tell different stories. Banach 2015, Mayo Clinic Proceedings concluded no significant benefit on statin-induced myopathy. Qu 2018, J Am Heart Assoc, with more included trials, concluded CoQ10 reduced muscle pain, weakness, cramps, and tiredness. The cleanest individual trial in confirmed myalgia (Taylor 2015) was negative. Neither ACC/AHA nor ESC/EAS recommend CoQ10 for statin myopathy as of 2026. Even so, it is the most informally co-recommended supplement in primary-care statin prescriptions.

Parkinson's disease (clearly negative). QE3 (Beal 2014, JAMA Neurology): 600 patients with early PD randomised to placebo, 1200 mg/day, or 2400 mg/day, with vitamin E. Stopped early for futility. Directionally worse on active treatment. The earlier Shults 2002, Arch Neurol signal did not replicate. Do not claim CoQ10 helps Parkinson's.

Hypertension (overstated). Rosenfeldt 2007, J Hum Hypertens meta-analysis reported drops of up to 17 mmHg systolic and up to 10 mmHg diastolic, numbers that get quoted everywhere. Rosenfeldt pooled 12 trials, and eight of them had no blinding. The 2016 Cochrane review (Ho, Cochrane Database) kept only blinded randomized trials. Pooling two of them (50 people) showed no significant drop (systolic −3.7 mmHg, not significant). Its verdict: moderate-quality evidence that CoQ10 has no clinically significant effect on blood pressure.

Primary mitochondrial disease (this is treatment, not supplement). Primary CoQ10 deficiency (COQ2, COQ4, COQ6, COQ8A, COQ9 mutations), MELAS, Leigh syndrome, certain steroid-resistant nephrotic syndromes. CoQ10 at 10 to 30 mg/kg/day is standard-of-care therapy in specialist mitochondrial-disease centres. Different drug, different dose, different patient.

Where the evidence is preclinical or retail-claim-driven.

• General "anti-aging". The levers that actually move the needle live in how to slow aging.
• VO2 max in healthy adults. Cooke 2008 (J Int Soc Sports Nutr) found no clear effect.
• Generic energy or fatigue claims in healthy people. EFSA rejected the energy-metabolism claim in 2010 (see the regulatory section).

One-line read: the strongest single piece of evidence is Q-SYMBIO. It used ubiquinone at 300 mg/day divided.

The trial-validated dose is 300 mg/day, split as 100 mg three times daily. Q-SYMBIO ran that schedule. Most retail CoQ10 bottles in DACH sell at 50 to 100 mg per softgel taken once a day. That is below the dose used in the trial. The Q-SYMBIO 300 mg/day finding applies to patients with NYHA III to IV chronic heart failure. It does not transfer to healthy adults, and using CoQ10 for a heart-failure indication should go through a cardiologist. For migraine prophylaxis, Sándor 2005 also used 3 x 100 mg/day.

Take it with fat. CoQ10 is highly lipophilic (fat-loving). Absorption rises a lot when you take it with a fat-containing meal. That is why oil softgels beat dry capsules in head-to-head pharmacokinetic studies. A softgel washed down with black coffee on an empty stomach wastes most of the dose.

Absorption saturates above about 200 mg per single dose. The fraction you absorb drops as the dose rises. If you are taking 200 to 300 mg/day, split it across two or three meals instead of one hit.

Plasma half-life is roughly 33 hours. Steady state takes about a week. Testing plasma CoQ10 within 24 h of a dose change tells you nothing useful. The standard is a trough sample (blood drawn just before your next dose) after 7+ days at a stable dose.

Drug interactions worth knowing.

• Warfarin and other coumarin blood thinners. CoQ10 shares the quinone structural motif (the same ring-shaped chemical core) with vitamin K. A 1994 case-report letter suggests it can mildly weaken warfarin's anticoagulant effect (Spigset 1994, The Lancet). A controlled trial points the other way. In a randomized double-blind placebo-controlled crossover trial of 24 patients (Engelsen et al., Thrombosis and Haemostasis 2002; Danish version Ugeskrift for Laeger 2003), CoQ10 at 100 mg/day did not change warfarin's clinical effect. INR (the standard clotting test) stayed stable, and the mean warfarin dose was 36.5 vs 36.0 mg/week on placebo. The case reports place the threshold at roughly 30 to 100 mg/day. Germany's risk agency BfR advises asking a doctor before taking more than 100 mg a day if you use a coumarin-type blood thinner (warfarin, phenprocoumon) ^[26]. Given the conflicting evidence, do not start or stop CoQ10 without telling your prescriber, and get an INR checked 1 to 2 weeks after either change.
• Antihypertensives. Rosenfeldt 2007 hinted at extra blood-pressure lowering, but the stricter Cochrane 2016 review found no meaningful effect. So a large extra drop is unlikely, but the interaction itself has not been properly studied ^[26]. BfR still advises a doctor's okay above 100 mg a day if you take blood-pressure drugs ^[26], and it is worth mentioning if you are already at goal on combination therapy.
• Theophylline, tamoxifen, certain chemotherapies. Mostly theoretical or single-case-report territory. Mention it to your oncology team before starting if you are on active treatment.
• Pregnancy, breastfeeding and under 18. Controlled human data are limited. Germany's risk agency BfR advises against relevant doses in pregnancy, breastfeeding and under 18 unless a doctor clears it ^[26]. Do not start without talking to your obstetrician.

Side effects at retail doses (100 to 300 mg/day). Generally very well tolerated. Most common complaints are mild GI upset (nausea, heartburn, diarrhoea), occasional headache, rare skin rashes ^[26], and rare insomnia when taken late in the day. None of these are unique to ubiquinol or ubiquinone. They track with dose and timing, not redox form. Doses above 300 mg a day are barely studied in healthy people ^[26].

CoQ10 in Germany, Austria, and Switzerland is sold only as a food supplement (Nahrungsergänzungsmittel / NEM), never a prescription drug. GKV, ÖGK, and LAMal do not reimburse routine wellness use. Even the bonus programmes at TK, Barmer, DAK, and AOK do not include CoQ10 in their wellness baskets in 2026.

Where to find it. Apotheken (physical and online: Shop-Apotheke, DocMorris, easyApotheke, Apotal), dm, Rossmann, Müller, Amazon, and direct-to-consumer brands (Sunday Natural, Sanct Bernhard, Pharma Nord). The drugstore chains (dm Mivolis, Rossmann Altapharma) carry CoQ10 mostly as a combination ingredient (Zellschutz blends, 65+ multivit), not as a standalone 100 mg monoproduct.

Brand snapshot (typical 2026 pricing, verify before buying).

The Kaneka seal. For ubiquinol products, the single most reliable consumer signal in DACH is the KanekaQH™ or Kaneka Ubiquinol® seal on the label. Most credible ubiquinol products in DACH carry it: Doppelherz system, Sanct Bernhard, Sunday Natural, Pure Encapsulations, Solgar, NaturaForte. A 60×100 mg ubiquinol pack much below €25 with no Kaneka mention is usually non-Kaneka (Chinese-fermented). Treat it with more scepticism on stability and assay accuracy.

The trial formulation question. Both trials used Pharma Nord's ubiquinone softgel: Q-SYMBIO at 300 mg/day (100 mg three times daily), KiSel-10 at 200 mg/day (100 mg twice daily) plus selenium.

DACH retail products carrying that formulation include Pharma Nord Bio-Quinone Gold (Myoqinon outside DACH), sold via Shop-Apotheke and pharmanord.de. The same formulation also sits behind the Mantle & Dybring 2020 review's framing, so factor in the competing-vendor disclosure.

Switzerland specifics. Burgerstein is the dominant Swiss Apotheke brand (30 mg × 180 caps ~CHF 67 at Coop Vitality; 100 mg × 30 caps ~CHF 33). Pure Encapsulations, Pharma Nord, and Naturecan CH (Kaneka Ubiquinol 50 mg) are also widely available. Swissmedic does not authorise food-supplement CoQ10; it falls under Swiss food law (the Food Act, LMG, overseen by the federal food-safety office BLV).

The price arithmetic. Per 100 mg, oil-softgel ubiquinol from Doppelherz, Sanct Bernhard or NaturaForte (€0.36 to 0.70) costs about the same as the Q-SYMBIO ubiquinone softgel (€0.73). The real spread is between powder-capsule ubiquinone (~€0.14 to 0.26) and premium brands (up to ~€1.83). A €5 monthly ubiquinone (vitamaze, RedcareVita) and a €55 monthly ubiquinol QH (Pure Encapsulations) deliver the same 100 mg of active substance per day. The 5 to 10x price spread is driven by form (ubiquinol > ubiquinone), carrier (oil softgel > dry powder), Kaneka licensing, channel (Apotheke > drogerie), and brand positioning. It is not driven by linearly more active product reaching your bloodstream.

Quality markers worth checking on the label.

1. Form declared explicitly (Ubiquinon or Ubiquinol, not vague "reduced CoQ10").
2. mg per softgel, not per "daily portion" (some 100-mg-marketed products split across two capsules).
3. Carrier in the ingredient list. MCT, sunflower lecithin, vitamin E, soybean oil, or olive oil for an oil softgel; rice flour or microcrystalline cellulose for a dry capsule.
4. Manufacturer named + Kaneka seal (for ubiquinol).
5. Certificate of analysis (CoA, the lab report on what is actually in the batch) available on request. Pure Encapsulations and Pharma Nord publish it in full; Sunday Natural publishes one per batch.

EU labels carry no CoQ10 health claims because EFSA assessed six claim categories in 2010 (energy metabolism, blood pressure, oxidative damage, cognition, cholesterol, endurance) and rejected all six for insufficient cause-and-effect evidence, a verdict no later opinion has overturned. So a label may state the substance and dose but make no structure/function benefit claim.

EFSA's Panel on Dietetic Products, Nutrition and Allergies reviewed CoQ10 health-claim dossiers in 2010 (EFSA Journal 2010;8(10):1793). The panel assessed six claim categories under Article 13(1) of Regulation (EC) No 1924/2006:

1. Contribution to normal energy-yielding metabolism
2. Maintenance of normal blood pressure
3. Protection of DNA, proteins, and lipids from oxidative damage
4. Contribution to normal cognitive function
5. Maintenance of normal blood cholesterol concentrations
6. Increase in endurance capacity and/or endurance performance

EFSA rejected all six. In each case, the panel concluded the cause-and-effect link between CoQ10 intake and the claimed benefit had not been established in the general population. No further EFSA opinion has substantiated a CoQ10 health claim in the fifteen years since.

The practical consequence is concrete. In the EU, a CoQ10 supplement label may state the substance and dose, but it may not legally make any structure-or-function claim about heart, energy, cholesterol, blood pressure, cognition, antioxidant defence, or athletic performance. Where you see such claims on packaging or websites in DACH, they are either non-compliant or routed through a personal-experience testimonial frame, which has its own consumer-protection issues.

This shapes the editorial frame of the guide. The studies discussed above (Q-SYMBIO, KiSel-10, Sándor, López-Lluch) are scientific evidence. They are not EU-authorised health claims. So this guide sticks to "what trials measured" and "associated with", not label-style benefit assertions.

Mitochondrial disease as a clinical indication sits outside the food-supplement regime. There, CoQ10 is prescribed by specialist physicians for one named patient or as a pharmacy-made (magistral) preparation. For everyone else, the regulatory reality is plain: food supplement, no authorised claims, no reimbursement, no medical-device-grade quality regime.

Is ubiquinol more bioavailable than ubiquinone? Sometimes, by some pharmacokinetic measures, in some formulations, in some populations, yes. By 2 to 3x across the board? The evidence from outside the ubiquinol industry does not support that. López-Lluch 2019 and Mantle & Dybring 2020 both conclude that carrier lipid and solubilisation drive bioavailability more than redox form. A well-formulated ubiquinone in oil can match or beat a poorly-formulated ubiquinol in a dry capsule.

Does ubiquinol produce better clinical outcomes? Not in the trials we have. Q-SYMBIO, the single positive heart-failure RCT, used ubiquinone at 300 mg/day. KiSel-10 used ubiquinone at 200 mg/day plus selenium. The Fladerer & Grollitsch 2023 review of 28 RCTs recommends ubiquinone over ubiquinol for people with heart failure.

Where does the "2 to 3x more bioavailable" line come from? From five studies: Hosoe 2007, Failla 2014 and Langsjoen 2014 from the Kaneka orbit, plus parallel cases like Evans 2009 (Soft-Gel Technologies) and Mei 2026 (Cocrystal Health). Each has a financial or organisational link to the maker of the ubiquinol product it tested. None of these papers is fraudulent. Each looks defensible on its own. Your job is to weigh the cumulative pattern of disclosed sponsor relationships.

Where is ubiquinol the defensible pick? Statin users, older adults, and people with fat-malabsorption conditions. The case in those groups is mechanistic and reasonable. It is not RCT-proven head-to-head against properly-formulated ubiquinone. If the price premium is small (oil-softgel ubiquinol often costs about the same per mg as the Q-SYMBIO ubiquinone softgel), fine. If you are comparing against cheap powder ubiquinone at 2 to 5x less per mg, the case is weaker than the headline "2 to 3x more bioavailable" line (repeated across many product pages) would suggest.

For everyone else. Either form, taken with a fat-containing meal, at an evidence-based dose (Q-SYMBIO used 300 mg/day divided), in a soft-gel format with a real lipid carrier (MCT, sunflower lecithin, vitamin E, soybean oil). That is the defensible choice. The lowest-priced clean ubiquinone soft-gel in oil is fine. The formulation is what is worth paying for, not the redox form.

One more point. The strongest single piece of CoQ10 evidence sits in a population (chronic heart failure NYHA III to IV) that is not the typical longevity-curious supplement buyer. Most people taking CoQ10 are taking it for vague "energy," statin side effects, or anti-aging. The clinical evidence in those populations is mixed (statin myopathy), surrogate-only (semen parameters), or absent (anti-aging in healthy adults). The mechanistic biology is real. The clinical case in the typical retail buyer is thinner than the headline messaging suggests, and that is true no matter which redox form is on the label.

The deeper biochemistry and the mitochondrial bigger picture sit in the Mitochondria guide. For other supplements, see Longevity Supplements.